Jazz Pharmaceuticals Reports Record 2025 Revenue, Driven by Xywav Growth
The low-sodium oxybate oral solution generated $1.7 billion in revenue, contributing to the company’s $3.1 billion neuroscience portfolio performance in 2025.
Read More
Author: SR Edit Staff
Nexalin Announces Pivotal Trial of HALO Clarity to Support FDA Submission for Insomnia
The 150-patient, decentralized study will evaluate the efficacy of deep intracranial frequency stimulation for the treatment of moderate to severe insomnia.
Read More
‘Measures of Sleep Are Decently Predictive of Preterm Birth’
A study using actigraphy finds that sleep consistency offers better predictive power of preterm birth than average sleep duration.
Read More
Sleep Medicine Advanced Practice Providers Now Have Their Own Foundation
SMAPP aims to bridge education gaps with a ‘by APPs, for APPs’ training model designed to elevate patient care.
Read More
First Patient Dosed in Phase 3 Trial of Solriamfetol for Major Depressive Disorder with Excessive Daytime Sleepiness
The CLARITY trial utilizes a randomized withdrawal design to assess time to relapse of depressive symptoms in patients with major depressive disorder and excessive daytime sleepiness.
Read More